Profile data is unavailable for this security.
About the company
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
- Revenue in USD (TTM)0.00
- Net income in USD-115.65m
- Incorporated1995
- Employees59.00
- LocationSavara Inc1717 Langhorne Newtown Road, Suite 300LANGHORNE 19047United StatesUSA
- Phone+1 (512) 614-1848
- Fax+1 (302) 636-5454
- Websitehttps://savarapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | 250.43m | -397.63m | 936.84m | 838.00 | -- | 1.30 | -- | 3.74 | -1.20 | -1.20 | 0.7552 | 1.82 | 0.2642 | 4.22 | 4.09 | 298,836.50 | -41.94 | -50.14 | -48.13 | -56.84 | 23.96 | -- | -158.78 | -1,097.64 | 3.00 | -- | 0.0014 | -- | 13,698.99 | -- | 16.18 | -- | 9.86 | -- |
| CareDx Inc | 358.00m | 60.76m | 943.79m | 644.00 | 22.78 | 3.03 | 12.54 | 2.64 | 0.8055 | 0.8055 | 6.15 | 6.05 | 0.7874 | 4.87 | 6.25 | 555,897.50 | 13.37 | -11.64 | 16.67 | -13.85 | 67.62 | 66.00 | 16.97 | -18.51 | 2.75 | -- | 0.00 | -- | 19.07 | 21.31 | 127.62 | -- | 14.13 | -- |
| Sana Biotechnology Inc | 0.00 | -234.41m | 945.60m | 194.00 | -- | 4.77 | -- | -- | -0.9708 | -0.9708 | 0.00 | 0.7447 | 0.00 | -- | -- | 0.00 | -47.13 | -39.42 | -51.39 | -43.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.82 | -- | 5.06 | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 955.87m | 162.00 | -- | 6.47 | -- | 6.70 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Vir Biotechnology Inc | 16.86m | -499.65m | 962.75m | 408.00 | -- | 1.21 | -- | 57.10 | -3.62 | -3.62 | 0.1223 | 5.73 | 0.0134 | -- | -- | 41,323.53 | -39.69 | -4.58 | -42.97 | -5.34 | 95.94 | -- | -2,963.54 | -13.27 | -- | -- | 0.00 | -- | -13.90 | 55.77 | 15.14 | -- | -3.97 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 970.00m | 106.00 | -- | 2.38 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.20 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| Savara Inc | 0.00 | -115.65m | 1.05bn | 59.00 | -- | 9.45 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.05bn | 160.00 | -- | 12.55 | -- | 94.60 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -210.50m | 1.05bn | 100.00 | -- | 3.26 | -- | -- | -3.33 | -3.33 | 0.00 | 4.54 | 0.00 | -- | -- | 0.00 | -45.83 | -- | -50.02 | -- | -- | -- | -- | -- | -- | -43.63 | 0.2021 | -- | -- | -- | -230.31 | -- | -- | -- |
| Septerna Inc | 22.05m | -58.81m | 1.09bn | 75.00 | -- | 2.81 | -- | 49.64 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 1.11bn | 35.00 | -- | 5.27 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.13bn | 130.00 | -- | 4.52 | -- | 75.19 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Savara Inc's reporting currency: US Dollar USD
23.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.99m | 4.42% |
| Nantahala Capital Management LLCas of 30 Sep 2025 | 8.78m | 4.31% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 7.60m | 3.74% |
| Vestal Point Capital LPas of 30 Sep 2025 | 4.02m | 1.97% |
| Rosalind Advisors, Inc.as of 30 Sep 2025 | 4.00m | 1.97% |
| Emerald Advisers LLCas of 30 Sep 2025 | 3.53m | 1.74% |
| Geode Capital Management LLCas of 30 Sep 2025 | 2.80m | 1.37% |
| Farallon Capital Management LLCas of 30 Sep 2025 | 2.50m | 1.23% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 2.43m | 1.20% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.36m | 1.16% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
